

**Table 1 - Demographic data, current clinical manifestations and disease activity/damage scores at herpes zoster infection (HZI) diagnosis in childhood systemic lupus erythematosus (SLE) and adult SLE patients.**

| Variables                                       | Childhood SLE<br>(n=38/362) | Adult SLE<br>(n=70/1,830) | P                 |
|---|-----------------------------|---------------------------|-------------------|
| <b>Demographic data</b>                         |                             |                           |                   |
| Disease duration until HZI diagnosis, months    | 21.5 (1-117)                | 62.5 (2-408)              | <b>0.001</b>      |
| Duration of HZI, days                           | 8 (5-23)                    | 10 (5-30)                 | 0.057             |
| Female gender                                   | 35 (92.1)                   | 62 (88.6)                 | 0.744             |
| <b>Clinical manifestations at HZI diagnosis</b> |                             |                           |                   |
| Fever   | 15/35 (42.9)                | 8/67 (11.9)               | <b>&lt;0.0001</b> |
| Hepatomegaly                                    | 2/36 (5.6)                  | 1/67 (1.5)                | 0.279             |
| Splenomegaly                                    | 0/36 (0)                    | 2/67 (3)                  | 0.541             |
| <b>Mucocutaneous involvement</b>                |                             |                           |                   |
| Malar rash                                      | 7/36 (19.4)                 | 6/68 (8.8)                | 0.132             |
| Discoid rash                                    | 0/33 (0)                    | 2/67 (3)                  | 1.000             |
| Photosensitivity                                | 6/36 (16.7)                 | 4/68 (5.9)                | 0.091             |
| Mucosal ulcers                                  | 2/36 (5.6)                  | 1/68 (1.5)                | 0.274             |
| Alopecia  | 3/36 (8.3)                  | 2/68 (2.9)                | 0.338             |
| <b>Musculoskeletal involvement</b>              |                             |                           |                   |
| Arthritis                                       | 2/36 (5.6)                  | 3/68 (4.4)                | 1.000             |
| Myositis  | 0 (0)                       | 0 (0)                     | 1.000             |
| <b>Serositis</b>                                |                             |                           |                   |
| Pleuritis                                       | 1/36 (2.8)                  | 1/68 (1.5)                | 1.000             |
| Pericarditis                                    | 1/36 (2.8)                  | 0/68 (0)                  | 0.346             |
| <b>Neuropsychiatric involvement</b>             |                             |                           |                   |
| Central nervous system                          | 1/36 (2.8)                  | 2/67 (3)                  | 1.000             |
| Peripheral nervous system                       | 0/36 (0)                    | 1/68 (1.5)                | 1.000             |
| <b>Nephritis</b>                                | 15/33 (45.5)                | 17/68 (25)                | <b>0.038</b>      |
| <b>Antiphospholipid syndrome</b>                | 0/25 (0)                    | 5/66 (7.6)                | 0.317             |
| <b>Other</b>                                    |                             |                           |                   |
| Arterial hypertension                           | 14/35 (40)                  | 12/68 (17.6)              | <b>0.017</b>      |
| Acute renal failure                             | 2/36 (5.6)                  | 6/68 (8.8)                | 0.711             |
| Chronic renal failure                           | 0/34 (0)                    | 1/68 (1.5)                | 1.000             |
| <b>Disease activity/damage at HZI diagnosis</b> |                             |                           |                   |
| SLEDAI-2K                                       | 8 (0-20)                    | 3 (0-18)                  | <b>0.002</b>      |
| SLEDAI-SK > 6                                   | 16 (42)                     | 18 (26)                   | 0.087             |
| SLICC/ACR-DI                                    | 0 (0-2)                     | 0 (0-3)                   | 0.933             |

Results are presented in n (%) median (range), SLEDAI-2K - Systemic Lupus Erythematosus Disease Activity Index 2000, SLICC/ACR-DI - Systemic Lupus International Collaborating Clinics/ACR - Damage Index.